XML 33 R24.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Fair value measurement | 9 Months Ended
--- | ---
Sep. 30, 2022
Fair value measurement | NOTE 16 – Fair value measurement: Financial items carried at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are classified in the tables below in one of the three categories of fair value levels:
|  | September 30, 2022 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
|  | (U.S. $ in millions) |
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money markets |  | $ | 897 |  |  | $ | — |  |  | $ | — |  |  | $ | 897 |
Cash, deposits and other |  |  | 1,328 |  |  |  | — |  |  |  | — |  |  |  | 1,328 |
Investment in securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity securities |  |  | 9 |  |  |  | — |  |  |  | — |  |  |  | 9 |
Other |  |  | 5 |  |  |  | — |  |  |  | 1 |  |  |  | 6 |
Restricted cash |  |  | 33 |  |  |  | — |  |  |  | — |  |  |  | 33 |
Derivatives: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset derivatives—options and forward contracts |  |  | — |  |  |  | 94 |  |  |  | — |  |  |  | 94 |
Liability derivatives: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options and forward contracts |  |  | — |  |  |  | (53 | ) |  |  | — |  |  |  | (53 | )
Bifurcated embedded derivatives |  |  | — |  |  |  | — |  |  |  | § |  |  |  | — |
Contingent consideration* |  |  | — |  |  |  | — |  |  |  | (113 | ) |  |  | (113 | )
Total |  | $ | 2,272 |  |  | $ | 41 |  |  | $ | (112 | ) |  | $ | 2,201 |
|  |  | December 31, 2021 |
|  |  | Level 1 |  |  |  | Level 2 |  |  |  | Level 3 |  |  |  | Total |
|  |  | (U.S. $ in millions) |
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money markets |  | $ | 220 |  |  | $ | — |  |  | $ | — |  |  | $ | 220 |
Cash, deposits and other |  |  | 1,945 |  |  |  | — |  |  |  | — |  |  |  | 1,945 |
Investment in securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity securities |  |  | 18 |  |  |  | — |  |  |  | — |  |  |  | 18 |
Other |  |  | 6 |  |  |  | — |  |  |  | 1 |  |  |  | 7 |
Restricted cash |  |  | 33 |  |  |  | — |  |  |  | — |  |  |  | 33 |
Derivatives: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset derivatives—options and forward contracts |  |  | — |  |  |  | 30 |  |  |  | — |  |  |  | 30 |
Liability derivatives: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options and forward contracts |  |  | — |  |  |  | (23 | ) |  |  | — |  |  |  | (23 | )
Bifurcated embedded derivatives |  |  | — |  |  |  | — |  |  |  | § |  |  |  | — |
Contingent consideration* |  |  | — |  |  |  | — |  |  |  | (176 | ) |  |  | (176 | )
Total |  | $ | 2,222 |  |  | $ | 7 |  |  | $ | (175 | ) |  | $ | 2,054 |
§ | Represents an amount less than $0.5 million.
* | Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor o f 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied ranged from 8.5% to 11.2%. The weighted average discount rate, calculated based on the relative fair value of Teva’s contingent consideration liabilities, was 8.9%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs:
|  | Nine months ended September 30, 2022 |  |  | Nine months ended September 30, 2021 |
|  | (U.S. $ in millions) |
Fair value at the beginning of the period |  | $ | (175 | ) |  |  | (258 | )
Redemption of debt securities |  |  | — |  |  |  | (9 | )
Bifurcated embedded derivatives |  |  | § |  |  |  | — |
Adjustments to provisions for contingent consideration: |  |  |  |  |  |  |  |
Actavis Generics transaction |  |  | (98 | ) |  |  | 21 |
Eagle transaction |  |  | (2 | ) |  |  | (14 | )
Settlement of contingent consideration: |  |  |  |  |  |  |  |
Actavis Generics transaction |  |  | 106 |  |  |  | — |
Eagle transaction |  |  | 68 |  |  |  | 74 |
Additional contingent consideration resulting from Novetide acquisition* |  |  | (11 | ) |  |  | — |
Fair value at the end of the period |  | $ | (112 | ) |  | $ | (186 | )
§ | Represents an amount less than $0.5 million.
* | In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies”. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net”, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.
Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):
|  | Estimated fair value* |
|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
Senior notes and sustainability-linked senior notes included under senior notes and loans |  | $ | 15,552 |  |  | $ | 21,477 |
Senior notes and convertible senior debentures included under short-term debt |  |  | 2,710 |  |  |  | 1,426 |
Total |  | $ | 18,262 |  |  | $ | 22,903 |
* | The fair value was estimated based on quoted market prices.

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration